Our data suggest that interfering with PHF8 expression might improve response to checkpoint blockade by inhibiting TGFβ signaling, yielding better clinical outcomes in melanoma patients with tumors refractory to programmed cell death protein 1 (PD1) inhibition. Here, PHF8 is linked to melanoma.